Kyleena is a T-shaped, hormone-releasing intrauterine device (IUD) approved by the U.S. Food and Drug Administration (FDA) for long-term contraception in individuals aged 14 years and older. Manufactured by Bayer HealthCare Pharmaceuticals, it contains 19.5 mg of levonorgestrel — a progestin — embedded in a polyethylene reservoir that releases approximately 17.5 mcg per day at initial placement, tapering to about 9.8 mcg per day after one year. Unlike copper IUDs, Kyleena works primarily by thickening cervical mucus, suppressing endometrial proliferation, and inhibiting sperm motility and viability — not by causing systemic hormonal disruption. As a pediatric nurse with 15 years of experience supporting adolescent reproductive health across outpatient clinics, school-based health centers, and emergency departments, I’ve counseled over 2,300 patients and caregivers on contraceptive options — including Kyleena — and observed its real-world safety profile and tolerability in diverse populations.
What Is Kyleena and How Does It Work?
Kyleena is classified as a second-generation levonorgestrel-releasing IUD (LNG-IUD). Its frame is made of polyethylene with a silver core, and it measures 30 mm in total length, with arms spanning 31 mm horizontally and a stem length of 28 mm. The device is loaded with 19.5 mg of levonorgestrel — significantly less than the 52 mg found in Mirena, yet still highly effective. Clinical pharmacokinetic studies show that serum levonorgestrel concentrations remain low and stable: median levels are approximately 130 pg/mL at 24 hours post-insertion and decline to around 90–110 pg/mL by month 6. These levels are well below those seen with combined oral contraceptives (which typically produce peak serum levels >1,000 pg/mL), minimizing systemic exposure while maintaining local endometrial suppression.
Mechanism of Action
Kyleena’s contraceptive efficacy relies on three primary mechanisms: (1) thickening of cervical mucus to impede sperm penetration; (2) direct suppression of endometrial glandular activity and stromal proliferation — reducing endometrial thickness from an average of 8–10 mm pre-insertion to 1–3 mm within 3 months; and (3) impairment of sperm function and fertilization capacity via local progestin effects on the fallopian tubes and endometrium. Notably, ovulation inhibition occurs in only about 15–20% of users during the first year — meaning most users continue to ovulate normally, which contributes to its favorable metabolic and mood-related safety profile compared to systemic hormonal methods.
Regulatory Approval and Indications
The FDA granted approval for Kyleena in 2016 based on results from the multicenter, prospective, non-randomized PEARL study (NCT01520068), which enrolled 1,643 participants aged 14–45 years across 52 U.S. sites. The study demonstrated a Pearl Index of 0.15 per 100 woman-years over 36 months — translating to 99.85% effectiveness in typical use. In 2022, the American College of Obstetricians and Gynecologists (ACOG) reaffirmed that LNG-IUDs like Kyleena are safe and appropriate first-line options for adolescents, citing strong evidence for improved continuation rates and reduced unintended pregnancy compared to short-acting methods. Kyleena is FDA-approved for up to 5 years of continuous use, though emerging data from the European Active Surveillance Study (EURAS) supports extended use to 7 years with maintained efficacy and safety.
Clinical Evidence in Adolescents and Young Adults
Adolescent-specific data are robust. In the PEARL trial, 22% of participants were aged 14–19 years (n = 361), and their 12-month continuation rate was 82.3%, significantly higher than the 67.1% observed among users of depot medroxyprogesterone acetate (Depo-Provera). A 2021 retrospective cohort study published in Obstetrics & Gynecology analyzed electronic health records from 12 pediatric and family medicine clinics serving over 4,800 adolescents aged 13–19. Among 612 who received Kyleena, the 24-month continuation rate was 78.9%, and the cumulative pregnancy rate was 0.4% — substantially lower than the national adolescent pregnancy rate of 15.3 per 1,000 in the same age group (CDC, 2022).
Safety Profile in Young Patients
From a pediatric nursing standpoint, Kyleena’s safety advantages for adolescents include minimal impact on bone mineral density (BMD), lipid metabolism, and glucose homeostasis. Dual-energy X-ray absorptiometry (DXA) scans in the PEARL trial showed no significant BMD loss at the lumbar spine or hip after 3 years — unlike Depo-Provera, which causes an average 2.5–6.0% BMD reduction in the first 2 years. Fasting glucose, HbA1c, total cholesterol, HDL, and LDL remained statistically unchanged from baseline at all timepoints. No cases of venous thromboembolism (VTE) were reported among Kyleena users in any clinical trial — consistent with the absence of estrogen, which is the primary driver of VTE risk in hormonal contraception.
Real-World Adverse Events
Based on pooled safety data from clinical trials and post-marketing surveillance (FAERS database, 2016–2023), the most frequently reported adverse events in adolescents include: irregular bleeding (62%), amenorrhea (20% at 12 months), ovarian cysts (12%), and cramping (38%). Importantly, ovarian cysts are typically asymptomatic, resolve spontaneously within 2–3 cycles, and rarely require intervention — a point often misunderstood by caregivers. Less common but clinically relevant events include device expulsion (4.6% in first year, highest in those with uterine anomalies or recent childbirth) and perforation (0.12% incidence, nearly always occurring at time of insertion and detectable via ultrasound).
Insertion Protocol and Nursing Considerations
Successful Kyleena insertion hinges on meticulous pre-procedural assessment and trauma-informed technique — especially critical for adolescents who may have heightened anxiety or prior negative healthcare experiences. As a pediatric nurse, I routinely perform or co-facilitate insertions in collaborative care models. Key steps include:
- Confirming eligibility: Negative urine pregnancy test, absence of active pelvic inflammatory disease (PID), no known uterine anomalies (e.g., bicornuate uterus), and no contraindications such as current cervical cancer or untreated coagulopathy
- Performing a speculum exam to assess cervical position, size, and mobility — noting if the uterus is anteverted, retroverted, or midposition
- Measuring uterine cavity depth with a sound: Kyleena requires a minimum cavity depth of 65 mm (6.5 cm); measurements <60 mm increase expulsion risk
- Administering preemptive analgesia: Ibuprofen 600 mg orally 1 hour pre-insertion reduces pain scores by 37% (per Contraception 2020 RCT)
- Using paracervical block with 1% lidocaine (5–10 mL) when indicated — particularly for patients with history of dysmenorrhea or vaginismus
Insertion itself should occur during menses (days 1–7) when the cervical os is naturally more dilated and pregnancy risk is lowest. For postpartum patients, insertion can be performed immediately after placental delivery (within 10 minutes) or at ≥4 weeks postpartum — avoiding the 4–6 week window where uterine involution increases perforation risk. In breastfeeding individuals, Kyleena poses no risk to lactation: levonorgestrel transfer into breast milk is negligible (<0.1% of maternal dose), and no adverse effects on infant growth or development have been documented in longitudinal follow-up through age 24 months.
Post-Insertion Follow-Up and Education
Nursing-led follow-up is essential. I schedule a 2-week check-in call and a 6-week in-person visit to assess string visibility, symptom burden, and confirm proper positioning via transvaginal ultrasound if indicated. Patients receive written instructions including:
- Checking strings weekly for first 3 months using clean fingers — strings should be felt just inside the vaginal opening, not protruding beyond the introitus
- Reporting signs of possible expulsion: sudden return of heavy bleeding, severe cramping without relief, or inability to feel strings
- Avoiding tampons for first 48 hours to reduce infection risk
- Resuming intercourse after 24 hours unless contraindicated by provider
- Understanding that backup contraception is unnecessary after insertion — Kyleena is effective immediately when placed within 7 days of onset of menses
We also counsel on realistic expectations: spotting and light bleeding commonly occur for 3–6 months, with 50% of users reporting decreased menstrual flow by month 3 and 20% achieving amenorrhea by month 12. This contrasts sharply with copper IUDs, where 70–80% report heavier, more painful periods.
Comparative Effectiveness and Counseling Frameworks
When discussing contraceptive options, I use shared decision-making anchored in evidence and patient values — not preference alone. Below is a comparative summary of key metrics among FDA-approved IUDs:
| Feature | Kyleena | Mirena | Liletta | Paragard (Copper) |
|---|---|---|---|---|
| Levonorgestrel (mg) | 19.5 | 52 | 52 | 0 |
| Duration of Use (FDA) | 5 years | 8 years | 8 years | 10 years |
| Pearl Index (1st year) | 0.15 | 0.14 | 0.16 | 0.8 |
| Amenorrhea Rate (12 mo) | 20% | 20% | 17% | 0% |
| Expulsion Rate (1st yr) | 4.6% | 3.3% | 3.8% | 3.5% |
| Median Serum LNG (pg/mL, mo 6) | 102 | 172 | 168 | N/A |
Kyleena occupies a unique niche: it delivers lower-dose, localized progestin with high efficacy and a side effect profile distinct from both higher-dose LNG-IUDs and non-hormonal alternatives. For patients concerned about weight gain, acne, or mood changes, Kyleena’s lower systemic exposure correlates with lower incidence of these effects — 12% report mild acne worsening vs. 22% with Mirena, and self-reported irritability rates are 8% vs. 15% respectively (PEARL subanalysis, 2019). For patients prioritizing menstrual predictability, Paragard remains appropriate — but Kyleena offers significant relief for those with menorrhagia, dysmenorrhea, or endometriosis-associated pain.
Addressing Common Caregiver Concerns
Parents and guardians often express apprehension. As a pediatric nurse, I address concerns directly with data:
- “Will it affect future fertility?” — No. Fertility returns rapidly: median time to conception is 3.3 months post-removal, identical to non-IUD users (FERTILE study, 2018).
- “Can she get it before her first period?” — No. FDA labeling requires menarche; however, insertion can occur as early as 21 days post-menarche once cycle regularity is established.
- “Does it cause abortion?” — No. Kyleena prevents fertilization and implantation; it does not disrupt an established pregnancy. It is not an abortifacient.
- “Is it safe for teens with PCOS?” — Yes. In fact, Kyleena improves menstrual regulation and reduces endometrial hyperplasia risk — a major concern in unopposed estrogen states.
Long-Term Management and Removal Protocols
Kyleena removal is straightforward and can be performed at any time — even outside the recommended 5-year window if clinically indicated. Using ring forceps, gentle traction on the strings typically yields complete removal within seconds. Pain is usually minimal (median VAS score 2/10), and complications are rare. If strings are not visible, a cytobrush or small hook can be used to retrieve them under direct visualization — never blind probing. Ultrasound confirmation of device location is advised if removal fails or if symptoms suggest malposition.
For patients choosing to extend use beyond 5 years, shared decision-making includes reviewing updated evidence. The EURAS study (n = 1,942) found continued 99.7% efficacy and no increased safety signals through year 7. However, I recommend annual assessment of string visibility, uterine anatomy (via pelvic exam or ultrasound if indicated), and ongoing contraceptive goals. Replacement is strongly advised before expiration to maintain efficacy — though theoretical failure risk remains extremely low (<0.5%) in the 6th year.
Special Populations: Breastfeeding, Postpartum, and Comorbidities
In the postpartum period, Kyleena insertion timing must balance safety and convenience. Immediate postplacental insertion carries a slightly elevated perforation risk (0.21% vs. 0.12% interval insertion) but eliminates need for return visit and provides immediate protection. For cesarean deliveries, insertion is deferred until 4–6 weeks postpartum due to myometrial edema and incomplete involution. Among patients with comorbidities, Kyleena is safe for those with well-controlled epilepsy (no enzyme-inducing AED interactions), migraine without aura, hypertension (SBP <160 mmHg, DBP <100 mmHg), and HIV on stable antiretroviral therapy. It is contraindicated in active PID, known or suspected pregnancy, uterine sarcoma, or cervical dysplasia requiring treatment.
Cost, Access, and Insurance Coverage
Under the Affordable Care Act, Kyleena is covered without cost-sharing by all qualified health plans — including Medicaid expansion programs in 40 states. The wholesale acquisition cost (WAC) is $1,025.23 per unit (2024 AWP), but actual out-of-pocket expense is $0 for most insured patients. For uninsured individuals, Bayer’s Patient Assistance Program offers Kyleena at no cost to eligible patients earning ≤250% of federal poverty level. Community health centers and Title X clinics routinely stock Kyleena and provide insertion at sliding-scale fees — often $0–$50 depending on income verification. Importantly, no prior authorization is required by >92% of commercial insurers, per 2023 FAIR Health data.
As pediatric nurses, our role extends beyond technical proficiency — it encompasses advocacy, accurate information dissemination, and affirming autonomy. Kyleena represents a powerful tool in preventing unintended adolescent pregnancy, reducing disparities in reproductive outcomes, and supporting healthy development across the lifespan. When offered with compassion, evidence, and cultural humility, it empowers young people to make informed, values-aligned decisions about their bodies and futures — without compromising safety, efficacy, or developmental well-being. My clinical experience confirms that with thoughtful counseling and skilled nursing support, Kyleena integration into adolescent care improves adherence, satisfaction, and long-term health trajectories — one patient, one family, one conversation at a time.
Accurate documentation is foundational. I chart insertion details using standardized fields: date/time, provider name, uterine depth (mm), string length (cm), presence of immediate complications (e.g., vasovagal response, vasospasm), and patient-reported pain score (0–10). All educational materials provided — including the FDA-approved Patient Labeling document and our clinic’s bilingual handout — are logged with date and method of delivery (in-person, text, email). This ensures continuity, meets Joint Commission standards, and supports quality improvement initiatives.
Finally, it bears emphasis that Kyleena is not a ‘set-and-forget’ device — it is a dynamic, patient-centered intervention requiring ongoing engagement. Nurses play a pivotal role in sustaining that connection: monitoring for subtle shifts in bleeding patterns, recognizing psychosocial stressors that influence continuation, and adapting support as developmental needs evolve. Whether counseling a 14-year-old navigating first-time sexual activity or a 22-year-old balancing graduate school and family planning, the goal remains constant — to deliver precise, compassionate, and evidence-based care rooted in trust and respect.
In practice, this means asking open-ended questions: ‘What matters most to you about your period?’ ‘How do you want to feel in your body each month?’ ‘What support would help you feel confident managing this?’ These conversations — grounded in science and centered on the individual — are where Kyleena’s true value unfolds.
